Ipilimumab

Phase 2Completed

0 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Platinum-sensitive Ovarian Cancer, Second-line, Third-line, or Fourth-line

Conditions

Platinum-sensitive Ovarian Cancer, Second-line, Third-line, or Fourth-line

Trial Timeline

Aug 21, 2012 → Jul 3, 2019

NCT ID

NCT01611558

About Ipilimumab

Ipilimumab is a phase 2 stage product being developed by Bristol Myers Squibb for Platinum-sensitive Ovarian Cancer, Second-line, Third-line, or Fourth-line. The current trial status is completed. This product is registered under clinical trial identifier NCT01611558. Target conditions include Platinum-sensitive Ovarian Cancer, Second-line, Third-line, or Fourth-line.

What happened to similar drugs?

0 of 1 similar drugs in Platinum-sensitive Ovarian Cancer, Second-line, Third-line, or Fourth-line were approved

Approved (0) Terminated (0) Active (1)

🔄ZL-2306(nirapairb) + PlacebosZai LabPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00495066	Pre-clinical	Completed	—	—	Melanoma
NCT06388369	Phase 1/2	Terminated	Aug 25, 2025	Mar 9, 2026	Very High Risk Prostate Carcinoma
NCT05074992	Phase 2	Terminated	Aug 24, 2022	May 2, 2023	Glioblastoma
NCT04635735	Phase 1/2	Terminated	Jan 12, 2020	Feb 2, 2023	Relapsed/Refractory Multiple Myeloma
NCT04196452	Pre-clinical	Active	Aug 12, 2019	Jul 24, 2034	Melanoma
NCT06566391	Phase 2	UNKNOWN	Mar 5, 2019	Dec 31, 2024	Melanoma
NCT02739386	Pre-clinical	Completed	Feb 29, 2016	Mar 30, 2017	Melanoma
NCT02516527	Phase 1	Completed	Oct 16, 2015	Sep 20, 2018	Melanoma
NCT02224768	Pre-clinical	Completed	Jul 1, 2015	Nov 1, 2015	Advanced Melanoma
NCT02279862	Phase 2	Completed	Dec 2, 2014	Dec 15, 2016	Prostate Cancer
NCT02107755	Phase 2	Completed	Sep 5, 2014	Aug 16, 2021	Liver Metastases
NCT02239900	Phase 1	Completed	Aug 26, 2014	Oct 25, 2019	Liver Cancer
NCT02113657	Phase 1	Completed	Aug 20, 2014	Nov 4, 2019	Prostate Cancer
NCT02221739	Phase 1/2	Completed	Jul 1, 2014	Oct 27, 2015	Non-small Cell Lung Cancer (NSCLC)
NCT02115139	Phase 2	Completed	Apr 4, 2014	Jul 31, 2018	Melanoma
NCT02050594	Pre-clinical	Completed	Feb 1, 2014	Feb 1, 2015	Melanoma
NCT01990859	Phase 2	Completed	Dec 1, 2013	Feb 1, 2015	Melanoma
NCT01696045	Phase 2	Terminated	Nov 12, 2012	Jul 31, 2016	Malignant Melanoma
NCT01703507	Phase 1	Completed	Nov 9, 2012	Apr 11, 2018	Recurrent Melanoma
NCT02662725	Phase 2	Completed	Sep 1, 2012	Dec 1, 2015	Melanoma

Competing Products

4 competing products in Platinum-sensitive Ovarian Cancer, Second-line, Third-line, or Fourth-line

See all competitors

Product	Company	Stage	Hype Score
Farletuzumab + Placebo	Eisai	Phase 2	35
OSE2101 + Pembrolizumab 25 MG/ML [Keytruda]	Merck	Phase 2	39
AK112 low dose + Chemotherapy + Olaparib + AK112 high dose	Akeso	Phase 2	42
ZL-2306(nirapairb) + Placebos	Zai Lab	Phase 3	30